Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Last trade$4.07
Day change+$0.025 (+0.62%)
Day range$3.91 – $4.10
Volume378,888
Market cap$390M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$390.48M
Price / earnings
—
Price / book
10.16×
Price / sales
49.34×
EV / sales
42.46×
EV / EBITDA
-5.47×
Profitability
Earnings per share
-$1.41
Return on assets
-143.4%
Return on equity
-355.57%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.9×
Current ratio
9.65×
Quick ratio
9.65×
Cash ratio
9.05×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$48.74M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IRD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.14M
$755K
$2.16M
$3.87M
$3.08M
$2.88M
$4.37M
$4.3M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.14M
$755K
$2.16M
$3.87M
$3.08M
$2.88M
$4.37M
$4.3M
Selling, general and administrative
$5.89M
$6.03M
$5.94M
$4.89M
$4.98M
$5.77M
$6.35M
$7.3M
Research and development
$14.49M
$11.21M
$10.58M
$10.43M
$6.41M
$6.02M
$7.95M
$7.03M
Total operating expenses
$20.38M
$17.24M
$16.52M
$15.32M
$11.39M
$11.79M
$14.3M
$42.33M
Operating income
-$19.25M
-$16.48M
-$14.36M
-$11.45M
-$8.31M
-$8.91M
-$9.93M
-$38.03M
Interest expense
$0
-$531K
-$651K
$1.28M
$0
$35K
-$1.37M
$0
Income before taxes
-$46.5M
-$8.1M
-$65.54M
-$16.52M
-$17.45M
-$7.42M
-$8.19M
-$35.14M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$46.5M
-$8.1M
-$65.54M
-$16.52M
-$17.45M
-$7.42M
-$8.19M
-$35.14M
Net income attributable to common shareholders
-$46.5M
-$8.1M
-$65.54M
-$16.52M
-$17.45M
-$7.42M
-$8.19M
-$35.14M
EBITDA
-$19.23M
-$16.47M
-$14.35M
-$11.44M
-$8.3M
-$8.89M
-$9.92M
-$38.02M
Basic earnings per share
-$0.46
-$0.08
-$0.75
-$0.20
-$0.25
-$0.12
-$0.24
-$1.16
Diluted earnings per share
-$0.46
-$0.14
-$0.75
-$0.20
-$0.25
-$0.12
-$0.24
-$1.16
Recent news
Company coverage with links to the original publishers.
Opus Genetics reported a quarterly loss of $0.18 per share, missing the consensus estimate of $0.14 by 28.57%, and posted revenues of $1.14 million, falling 43.8% short of expectations. The company has underperformed consensus estimates in 3 of the last 4 quarters. Despite a 109% year-to-date gain, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Opus Genetics announced completion of dosing in Cohort 2 of its OPGx-BEST1 Phase 1/2 trial with data expected in Q1 2027. The company also reported full enrollment of its OPGx-LCA5 Phase 3 registrational trial with dosing to begin in Q4 2026, FDA clearance for OPGx-RDH12, and FDA approval of phentolamine ophthalmic solution for presbyopia. With $89 million in cash, the company projects runway into 2029.
Opus Genetics announced completion of dosing in Cohort 2 of its BIRD-1 Phase 1/2 clinical trial for OPGx-BEST1, a gene therapy for BEST1-related retinal diseases. The higher-dose cohort enrolled 11 participants (exceeding the target of 5) at 4.5 × 10⁹ vg/eye. Topline three-month data is expected in Q1 2027, with potential Phase 3 pivotal trial dosing anticipated in H2 2027. Cohort 1 showed favorable safety and clinically meaningful improvements in visual function across all five participants.
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% (RYZUMVI®) for treating presbyopia in adults, expanding its previous indication for pharmacologically-induced mydriasis. The approval was supported by positive Phase 3 VEGA-2 and VEGA-3 trial results and will trigger a milestone payment from commercial partner Viatris Inc. Presbyopia affects approximately 90% of U.S. adults over 45, and the drug offers a non-invasive treatment option.
Opus Genetics announced plans to present topline clinical data from Phase 1/2 Cohort 1 of its OPGx-BEST1 gene therapy program during an investor conference call on September 9, 2026. The company will also present full clinical datasets and additional analyses at several upcoming ophthalmology conferences including Euretina, Retina in Rio, and FLORetina.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.